2/3
07:00 am
kalv
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/2
03:51 pm
kalv
TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results [Yahoo! Finance]
Low
Report
TD Cowen Bullish on KalVista Pharmaceuticals, Inc. (KALV) Ahead of Q4 Results [Yahoo! Finance]
1/24
05:09 am
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
1/9
08:02 am
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at HC Wainwright from $27.00 to $37.00. They now have a "buy" rating on the stock.
Medium
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at HC Wainwright from $27.00 to $37.00. They now have a "buy" rating on the stock.
1/8
04:27 pm
kalv
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results [Yahoo! Finance]
Medium
Report
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results [Yahoo! Finance]
1/8
04:05 pm
kalv
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
Medium
Report
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
1/6
08:00 am
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at Needham & Company LLC from $28.00 to $32.00. They now have a "buy" rating on the stock.
Low
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at Needham & Company LLC from $28.00 to $32.00. They now have a "buy" rating on the stock.
12/22
06:00 am
kalv
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
Low
Report
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema
12/4
08:05 am
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
High
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $28.00 price target on the stock.
12/3
03:13 pm
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Low
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its "buy" rating reaffirmed by analysts at Cowen Inc.
11/18
06:38 am
kalv
Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects [Yahoo! Finance]
Low
Report
Citizens Touts KalVista Pharmaceuticals, Inc. (KALV) Growth Trajectory on EKTERLY Prospects [Yahoo! Finance]
11/11
04:26 pm
kalv
KalVista Pharmaceuticals Inc (KALV) Q3 2026 Earnings Call Highlights: Strong EKTERLY Launch and ... [Yahoo! Finance]
High
Report
KalVista Pharmaceuticals Inc (KALV) Q3 2026 Earnings Call Highlights: Strong EKTERLY Launch and ... [Yahoo! Finance]
11/11
01:42 pm
kalv
KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
KalVista Pharmaceuticals, Inc. (KALV) Q3 2025 Earnings Call Transcript [Seeking Alpha]
11/11
09:06 am
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target lowered by analysts at Citizens Jmp from $29.00 to $28.00. They now have a "market outperform" rating on the stock.
Low
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target lowered by analysts at Citizens Jmp from $29.00 to $28.00. They now have a "market outperform" rating on the stock.
11/11
07:03 am
kalv
KalVista Pharmaceuticals (NASDAQ:KALV) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
KalVista Pharmaceuticals (NASDAQ:KALV) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
11/10
07:41 pm
kalv
KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
Medium
Report
KalVista Pharmaceuticals, Inc. (KALV) Reports Q3 Loss, Tops Revenue Estimates [Yahoo! Finance]
11/10
05:17 pm
kalv
KalVista Pharmaceuticals GAAP EPS of -$0.92, revenue of $13.69M [Seeking Alpha]
Low
Report
KalVista Pharmaceuticals GAAP EPS of -$0.92, revenue of $13.69M [Seeking Alpha]
11/10
05:00 pm
kalv
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results [Yahoo! Finance]
Low
Report
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results [Yahoo! Finance]
11/10
04:30 pm
kalv
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results
Medium
Report
KalVista Pharmaceuticals Provides Operational Update and Reports Third Quarter Financial Results